drugset / Trial / NCT00101179

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00101179

Phase 1 Completed 63 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MS-275 together with azacitidine may kill more cancer cells. This phase I trial is studying the side effects and best dose of MS-275 when given together with azacitidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.

Timeline

Start
2004-11-03
Primary completion
2011-04-20
Completion
2014-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified Subcutaneous
Subject Entinostat Small molecule Oral